The resurgence of scientific interest in psychedelics has opened new frontiers across three interrelated domains: altered states of consciousness, cultural and contextual influences, and clinical practice. This review synthesizes current evidence on how psychedelic substances and therapies engage (a) mechanisms of consciousness, (b) culture and context (e.g., ritual, set and setting, sociocultural meaning), and (c) clinical implementation (therapeutic outcomes, integration, ethics, training). Drawing on recent systematic reviews, clinical trials, anthropological studies, and policy/ethical frameworks, this study maps key findings, identifies gaps, and proposes an integrative agenda for the field. In terms of consciousness, emerging data link subjective experience (e.g., mystical-type states, ego dissolution) with therapeutic outcomes, while neurobiological models (e.g., neural plasticity, entropy) remain under investigation. In cultural/contextual terms, research emphasizes the role of set and setting, historic indigenous uses, and the need for equity, inclusion, and culturally-informed frameworks. In clinical practice, evidence for safety and efficacy in select conditions is promising but nascent; meanwhile, ethical, training, and health-system issues loom large. This research argues that meaningful progress demands a framework that bridges these three axes—only by consciously integrating phenomenology, culture, and care can psychedelic research mature into a responsible, scalable therapeutic practice. Key recommendations include standardizing phenomenological measurement, ensuring culturally responsible trial design, embedding integration and follow-up in clinical workflows, and fostering practitioner competency and equity.